TPST
Tempest Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.48
+1.41%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.47
From 52W high−95.22%
Volume70386.00
Market cap$9.50M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$0.47
From 52W high
−95.22%
Volume
70386.00
Market cap
$9.50M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
30.6
MomentumView details →
1D Return
+1.41%
YTD Return
−83.11%
SummaryUpdated Jun 1, 2026
Tempest Therapeutics, Inc. (NASDAQ:TPST) is a clinical-stage biotechnology company founded in 2011 and headquartered in South San Francisco, California. Originally established as a subsidiary of Inception Sciences, Inc., the company went public in November 2012. Tempest focuses on developing innovative small molecule therapeutics specifically designed to treat various forms of cancer, with a particular emphasis on targeting immune system pathways that can enhance the body's natural ability to fight tumors.
Similar companies
Latest newsMore news →
Tempest Therapeutics announced that Constance Ames resigned as chief financial officer and Stephanie Horn-Warnock was appointed chief financial officer, principal financial and accounting officer, treasurer, and corporate secretary, effective October 26, 2026.5d agoTempest Therapeutics, Inc. Chief Financial Officer Nicholas Rossettos resigned, effective September 22, 2026.37d ago